Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo

Journal of the National Cancer Institute

Volumn 92, Issue 23, 2000, Pages 1926-1934

  Schiff, Rachel ^a   Reddy, Praveen ^a   Ahotupa, Markku ^b   Coronado Heinsohn, Ester ^c   Grim, Matt ^c   Hilsenbeck, Susan G ^a   Lawrence, Richard ^d   Deneke, Susan ^c   Herrera, Rafael ^a   Chamness, Gary C ^a   Fuqua, Suzanne A W ^a   Brown, Powel H ^a   Osborne, C Kent ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TURKU   (Finland)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTIOXIDANT; APROTININ; ARACHIS OIL; CASTOR OIL; CHLORAMPHENICOL ACETYLTRANSFERASE; DNA; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEXOSE; HYDROGEN PEROXIDE; LEUPEPTIN; LIPID PEROXIDE; OXYGEN; PHORBOL 13 ACETATE 12 MYRISTATE; PICRYL CHLORIDE; PROTEIN C JUN; PROTEINASE; PROTEINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE; TAMOXIFEN CITRATE; TRANSCRIPTION FACTOR AP 1; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER TRANSPLANTATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GLUTATHIONE METABOLISM; GROWTH STIMULATION; HEXOSE MONOPHOSPHATE SHUNT; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID PEROXIDATION; MOUSE; NONHUMAN; NUDE MOUSE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TRANSCRIPTION REGULATION; WESTERN BLOTTING; XENOTRANSPLANTATION;

EID: 0034614098     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.23.1926     Document Type: Article

References (58)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
3. Estrogen receptors: Ligand discrimination and antiestrogen action
4. Antiestrogens: Mechanisms and actions in target cells
5. Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen
6. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
7. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
8. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
9. Tamoxifen-induced tumor stimulation and withdrawal response
10. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites
11. Mechanisms of tamoxifen resistance
12. Peroxidase-catalyzed pro- versus antioxidant effects of 4-hydroxytamoxifen: Enzyme specificity and biochemical sequelae
13. Tamoxifen reduces endogenous and UV light-induced oxidative damage to DNA, lipid and protein in vitro and in vivo
14. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins
15. Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression
16. Alterations of drug metabolizing and anti-oxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat
17. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor
18. Antioxidant and redox regulation of gene transcription
19. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
20. The stress-activated protein kinase subfamily of c-Jun kinases
21. 2. Role in cell survival following oxidant injury
22. Tamoxifen activation of the estrogen receptor/ AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
23. Transcriptional activities of estrogen and glucocorticoid receptors are functionally integrated at the AP-1 response element
24. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites
25. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor
26. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
27. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis
28. Activation and inhibition of the AP-1 complex in human breast cancer cells
29. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice
30. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells
31. Lucigenin and linoleate enhanced chemiluminescent assay for superoxide dismutase activity
32. A spectrophotometric method of measuring the breakdown of hydrogen peroxide by catalase
33. Glutathione S-transferase. The first enzymatic step in mercapturic acid formation
34. Further studies on the properties and assay of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase of rat liver
35. Carbon tetrachloride, bromotrichloromethane and ethanol acute intoxication. New chemical evidence for lipid peroxidation in rat tissue microsomes
36. Measurement of glutathione-protein mixed disulfides
37. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
38. The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation
39. Lead suppresses chimeric human transferrin gene expression in transgenic mouse liver
40. Lipid peroxidation and tissue damage
41. Glutathione
42. The regulation of AP-1 activity by mitogen-activated protein kinases
43. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
44. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation
45. The level of intracellular glutathione is a key regulator for the induction of stress-activated signal transduction pathways including Jun N-terminal protein kinases and p38 kinase by alkylating agents
46. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors
47. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells
48. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
49. Vascular effects of estrogens: Rapid actions, novel mechanisms, and potential therapeutic implications
50. Physiological melatonin inhibition of human breast cancer cell growth in vitro: Evidence for a glutathione-mediated pathway
51. Induction of AP-1 (Fos/Jun) by chemical agents mediates activation of glutathione S-transferase and quinone reductase gene expression
52. Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen
53. Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents
54. The quinone reductase gene: A unique estrogen receptor-regulated gene that is activated by antiestrogens
55. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity
56. Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro
57. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance
58. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant pheno-type